帕金森病和基于线粒疗法的方法对抗α-Synucleinopathies
Vidhi Bhatt1, Halak Shukla1, Anand Krishna Tiwari1
1Genetics & Developmental Biology Laboratory, Department of Biotechnology & Bioengineering, Institute of Advanced Research (IAR), 382426 Gandhinagar, Gujarat, India.
Journal of integrative neuroscience
|June 28, 2024
概括
线粒体功能障碍与帕金森病 (PD) 病原发生有关,影响神经元健康. 本综述探讨了针对α-synucleinopathies的基于线粒体的治疗方法,用于PD治疗.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 涉及多巴胺能神经元损失和α-synuclein聚合.
- 线粒体是PD病原体的核心,其功能障碍导致生物能量缺陷和氧化应激.
- 线粒体变化有助于家族性和零星性PD的神经退行.
研究的目的:
- 审查目前基于线粒体的帕金森病治疗策略.
- 为了突出线粒体在α-synucleinopathies中的作用.
- 探索改善PD中线粒体健康的新方法.
主要方法:
- 关于线粒体和帕金森病研究的文献综述.
- 针对线粒体功能障碍的治疗干预措施的分析.
- 与α-synuclein和线粒体通路相关的发现的综合.
主要成果:
- 线粒体功能障碍,包括生物能量损害和氧化应激,是PD的关键特征.
- 准线粒体提供了PD中神经保护的潜力.
- 治疗策略旨在恢复线粒体功能,并对抗α-synuclein毒性.
结论:
- 线粒体是帕金森病的有希望的治疗点.
- 开发增强线粒体健康的治疗方法可能会缓解PD症状.
- 对基于线粒体的治疗方法的进一步研究对于对抗α-synucleinopathies至关重要.
关键词:
莱维的身体.帕金森病是帕金森病的一种.线粒体中的线粒体.线粒体的动力学甲基疗法 (mitotherapy) 是一种治疗方法.α-Synucleinopathies是指α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synucleinopathies,即α-Synuclein相关概念视频
Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K


